ATE536367T1 - Bindende peptidomimetika und deren verwendungen - Google Patents

Bindende peptidomimetika und deren verwendungen

Info

Publication number
ATE536367T1
ATE536367T1 AT05723375T AT05723375T ATE536367T1 AT E536367 T1 ATE536367 T1 AT E536367T1 AT 05723375 T AT05723375 T AT 05723375T AT 05723375 T AT05723375 T AT 05723375T AT E536367 T1 ATE536367 T1 AT E536367T1
Authority
AT
Austria
Prior art keywords
monomers
nucleic acid
disclosed
acid molecule
recombinant expression
Prior art date
Application number
AT05723375T
Other languages
English (en)
Inventor
Mark Greene
Ramachandran Murali
Hongtao Zhang
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Application granted granted Critical
Publication of ATE536367T1 publication Critical patent/ATE536367T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/36—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Actinomyces; from Streptomyces (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0089—Oxidoreductases (1.) acting on superoxide as acceptor (1.15)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT05723375T 2004-02-20 2005-02-18 Bindende peptidomimetika und deren verwendungen ATE536367T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54622404P 2004-02-20 2004-02-20
PCT/US2005/005383 WO2005081898A2 (en) 2004-02-20 2005-02-18 Binding peptidomimetics and uses of the same

Publications (1)

Publication Number Publication Date
ATE536367T1 true ATE536367T1 (de) 2011-12-15

Family

ID=34910756

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05723375T ATE536367T1 (de) 2004-02-20 2005-02-18 Bindende peptidomimetika und deren verwendungen

Country Status (7)

Country Link
US (1) US7906624B2 (de)
EP (2) EP2392586A1 (de)
JP (1) JP2007528725A (de)
AT (1) ATE536367T1 (de)
AU (1) AU2005216126B2 (de)
CA (1) CA2556832A1 (de)
WO (1) WO2005081898A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003099845A2 (en) 2002-05-23 2003-12-04 Trustees Of The University Of Pennsylvania Fas peptide mimetics and uses thereof
US20090110662A1 (en) * 2007-04-30 2009-04-30 Intezyne Technologies, Inc. Modification of biological targeting groups for the treatment of cancer
JP5963341B2 (ja) * 2007-09-14 2016-08-10 アムジエン・インコーポレーテツド 均質な抗体集団
US20130231385A1 (en) 2010-05-28 2013-09-05 The Board Of Regents Of The University Of Texas Systems Oligo-benzamide compounds and their use
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
US8754124B2 (en) 2011-11-23 2014-06-17 Board Of Regents, The University Of Texas System Oligo-benzamide compounds and their use in treating cancers
US8835493B2 (en) 2011-11-23 2014-09-16 Board Of Regents, The University Of Texas System Oligo-benzamide compounds for use in treating cancers
TWI731535B (zh) 2014-03-21 2021-06-21 美商艾伯維有限公司 抗-egfr抗體及抗體藥物結合物
CN107847544B (zh) * 2015-07-20 2021-10-15 小利兰·斯坦福大学董事会 用多聚体结合试剂检测细胞表型和定量
CN109641962A (zh) 2016-06-08 2019-04-16 艾伯维公司 抗b7-h3抗体和抗体药物偶联物
JP2019526529A (ja) 2016-06-08 2019-09-19 アッヴィ・インコーポレイテッド 抗b7−h3抗体及び抗体薬物コンジュゲート
RS61828B1 (sr) 2016-06-08 2021-06-30 Abbvie Inc Anti-b7-h3 antitela i antitelske konjugacije lekova
WO2017214456A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-cd98 antibodies and antibody drug conjugates
EP3554544A4 (de) 2016-12-16 2020-07-29 Bluefin Biomedicine, Inc. Anti-cub-haltige protein 1-(cdcp1)-antikörper, antikörper-wirkstoff-konjugate und verfahren zur verwendung davon
WO2018195302A1 (en) 2017-04-19 2018-10-25 Bluefin Biomedicine, Inc. Anti-vtcn1 antibodies and antibody drug conjugates
CN107236046B (zh) * 2017-05-15 2021-05-07 江苏吴中医药集团有限公司苏州中凯生物制药厂 一种重组人内皮抑素融合蛋白及其制备方法和应用
WO2018231827A1 (en) 2017-06-12 2018-12-20 Bluefin Biomedicine, Inc. Anti-il1rap antibodies and antibody drug conjugates
EP3652195A4 (de) 2017-07-10 2021-08-04 SRI International Peptidsaporinkonjugat zur behandlung von krebs
WO2019014190A1 (en) 2017-07-10 2019-01-17 Brown Kathlynn C MOLECULAR GUIDANCE SYSTEM PEPTIDES AND USES THEREOF
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
WO2025027529A1 (en) 2023-07-31 2025-02-06 Advesya Anti-il-1rap antibody drug conjugates and methods of use thereof
TW202530255A (zh) 2023-12-15 2025-08-01 法商亞維西亞有限公司 抗il-1rap結合結構域及其抗體-藥物偶聯物
CN119462826B (zh) * 2025-01-13 2025-04-25 成都普康唯新生物科技有限公司 一种伪肽化合物及其制备方法与应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5334702A (en) 1991-03-25 1994-08-02 University Of Illinois Compositions which are immunologically crossreactive with antibodies and preparative methods therefor
US5328985A (en) 1991-07-12 1994-07-12 The Regents Of The University Of California Recombinant streptavidin-protein chimeras useful for conjugation of molecules in the immune system
US5665539A (en) 1991-07-12 1997-09-09 The Regents Of The University Of California Immuno-polymerase chain reaction system for antigen detection
US6391590B1 (en) 1991-10-21 2002-05-21 The Regents Of The University Of California Recombinant streptavidin-metallothionein chimeric protein having biological recognition specificity
US5879657A (en) 1993-03-30 1999-03-09 The Dupont Merck Pharmaceutical Company Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders
US6100377A (en) 1994-06-10 2000-08-08 The Trustees Of The University Of Pennsylvania Constrained peptides
US5663144A (en) 1995-05-03 1997-09-02 The Trustees Of The University Of Pennsylvania Compounds that bind to p185 and methods of using the same
US6497881B1 (en) 1995-11-30 2002-12-24 New York University High efficiency tissue specific compound delivery system using streptavidin-protein a fusion protein
US6451995B1 (en) 1996-03-20 2002-09-17 Sloan-Kettering Institute For Cancer Research Single chain FV polynucleotide or peptide constructs of anti-ganglioside GD2 antibodies, cells expressing same and related methods
US5922553A (en) 1996-11-21 1999-07-13 Trustees Of The University Of Pennsylvania Method of detecting protein by immuno RNA
US7026446B1 (en) * 1997-12-24 2006-04-11 Diatech Pty Ltd. Bifunctional molecules
JP2002523041A (ja) 1998-08-25 2002-07-30 ユニバーシティ オブ ワシントン 第2の機能的ドメインを有するストレプトアビジン変異体
US7144991B2 (en) 1999-06-07 2006-12-05 Aletheon Pharmaceuticals, Inc. Streptavidin expressed gene fusions and methods of use thereof
US6743592B1 (en) 2000-07-25 2004-06-01 The Trustees Of The University Of Pennsylvania Methods, systems and kits for immuno-detection of epitopes expressed on molecules
US7045286B2 (en) 2000-07-25 2006-05-16 The Trustees Of The University Of Pennsylvania Methods of detecting molecules expressing selected epitopes via fluorescent dyes
US7524628B2 (en) 2000-07-25 2009-04-28 The Trustees Of The University Of Pennsylvania Method for detecting molecules expressing a selected epitope via fluorescent dyes
US6998234B2 (en) 2000-11-03 2006-02-14 Oncotech, Inc. Methods for cancer prognosis and diagnosis relating to tumor vascular endothelial cells
US7179785B2 (en) * 2001-11-21 2007-02-20 The Trustees Of The University Of Pennsylvania Compounds that bind to p185 and methods of using the same

Also Published As

Publication number Publication date
EP1718323B1 (de) 2011-12-07
HK1100260A1 (en) 2007-09-14
WO2005081898A2 (en) 2005-09-09
US20080206136A1 (en) 2008-08-28
US7906624B2 (en) 2011-03-15
CA2556832A1 (en) 2005-09-09
AU2005216126B2 (en) 2011-04-07
AU2005216126A1 (en) 2005-09-09
WO2005081898A3 (en) 2006-02-02
EP1718323A2 (de) 2006-11-08
JP2007528725A (ja) 2007-10-18
EP1718323A4 (de) 2008-12-31
EP2392586A1 (de) 2011-12-07

Similar Documents

Publication Publication Date Title
WO2005081898A3 (en) Binding peptidomimetics and uses of the same
Wenzel et al. Conformational constraints in protein degradation by the 20S proteasome
PE20081140A1 (es) Agentes terapeuticos a base de peptidos derivados de toxinas
UY31123A1 (es) Proteinas de fusion natriureticas
ATE550041T1 (de) Transglutaminase-vermittelte konjugation von peptiden
FI3778885T3 (fi) Muokattujen ihmisen arginaasien koostumuksia ja menetelmiä syövän hoitamiseksi
PH12013502425B1 (en) Smoothened polypeptides and methods of use
ATE416190T1 (de) Polypeptide mit bindungsaffinität für her2
AR072680A1 (es) Axmi-115 axmi-113 axmi-005 axmi-163 y axmi-184 proteinas insecticidas y metodos de uso de las mismas
CL2008000912A1 (es) Proteina insecticida hibrida que comprende dos proteinas cry del bacillus thuringiensis (bt) diferentes; molecula de acido nucleico que comprende dicha proteina; casete de expresion, vector recombinante que comprenden el acido nucleico; celula transg
BRPI0716416A2 (pt) polipeptídeo substancialmente puro entre 37 e 47 besíduos de aminoácido de comprimento, ácido nucléico isolado, vetor: célula hospedeira e composição farmacêutica
AR059300A1 (es) Peptidos inhibidores de la fusion de vih con propiedades biologicas mejoradas
EA200900404A1 (ru) Новые гены, родственные гену глутаминилциклазы
BRPI0514396A2 (pt) polipeptìdeos dependentes de vitamina k modificada
NZ580378A (en) Recombinant expression vector elements (reves) for enhancing expression of recombinant proteins in host cells
DK1549333T3 (da) Compstatinanaloge med forbedret aktivitet
AR038568A1 (es) Anticuerpos anti-a beta y su uso
BRPI0811333A2 (pt) "proteína de fusão compreendida de taci truncado e de imunoglobulina fc, sequência de dna, vetor, célula, uso da proteína de fusão e composição farmacêutica"
PE20120425A1 (es) Metodos y composiciones en base a la proteina tipo 2 de la toxina shiga
DK1618128T3 (da) Tuberkulosevaccine med forbedret effektivitet
WO2008040190A8 (fr) Petits peptides pour anti-angiogenèse et utilisation de ceux-ci
DE69941433D1 (de) Von protease typ ii spaltbares peptid
NZ334839A (en) Polynucleotide molecules encoding neospora proteins and uses thereof
SE0301987D0 (sv) New polypeptide
ATE466874T1 (de) Mit scytovirin der domäne 1 verwandte polypeptide